| INTRODUCTION
Ranolazine is an antianginal agent with a relatively unique mode of action. Specifically, its anti-ischemic effects are mediated via inhibition of the late sodium current (I NaL ), which in turn through reverse sodium-calcium exchange improves diastolic compliance (Antzelevitch, Burashnikov, Sicouri, & Belardinelli, 2011) . The Metabolic Efficiency with Ranolazine for Less Ischemia in Non-STElevation Acute Coronary Syndrome: Thrombolysis in Myocardial Infarction (MERLIN TIMI) 36 trial (NCT00099788), which enrolled 6,560 patients, showed the drug to be safe and effective as antianginal therapy . Subanalyses of the results revealed that ranolazine suppressed nonsustained ventricular tachycardia and reduced mortality among patients with elevated T-wave alternans (Nieminen et al., 2014) , a marker of risk for lethal arrhythmia . These conclusions are consistent with preclinical studies demonstrating potent antiarrhythmic properties (Kumar et al., 2008; Nieminen et al., 2011) . In a large animal model of partial coronary artery stenosis, Nieminen et al. (2011) reported that ranolazine significantly blunted the ischemia-induced fall in ventricular fibrillation threshold and reduced T-wave alternans, indicating the drug's capacity to protect against repolarization heterogeneity, which underlies propensity for reentrant arrhythmias.
Recently, a noninvasive method has been developed to assess repolarization heterogeneity using second central moment analysis of the interlead splay of T waves in precordial leads about a mean waveform as the central axis. This parameter, termed "T-wave heterogeneity" (TWH), was shown to predict sudden cardiac death in over 5,600 subjects enrolled in Health Survey 2000, which was designed to provide a cross-section of the entire Finnish population (Kenttä et al., 2016) .
The goal of the present secondary analysis was to evaluate the effect of ranolazine on TWH in patients participating in the Effects of Ranolazine on Coronary Flow Reserve in Symptomatic Patients with Diabetes and Suspected or Known Coronary Artery Disease (RAND-CFR) trial (NCT01754259). Diabetic patients are at risk for mortality in large part due to cardiac electrical instability that results from autonomic neuropathy resulting in adrenergic predominance (Carnethon, Golden, Folsom, Haskell, & Liao, 2003) and from repolarization abnormalities reflected in increased QT dispersion (Arildsen, May, Christiansen, & Damsgaard, 1999; Cardoso, Salles, Bloch, Deccache, & Siqueira-Filho, 2001; Wei, Dorian, Newman, & Langer, 1995) . As experimental studies indicate that ranolazine can protect against these adverse factors, we hypothesized that ranolazine will suppress TWH in RAND-CFR patient cohort, who exhibited nonflow-limiting coronary artery stenosis with diffuse atherosclerosis and/or microvascular dysfunction. Furthermore, based on findings in large animals with concurrent measurement of coronary artery blood flow and repolarization abnormalities (Nieminen et al., 2011), we postulated that alterations in TWH will occur despite the absence of effects on myocardial blood flow (MBF), which was shown in the parent study (Shah et al., 2017) .
| METHODS

| Study design
We studied all 16 patients from the double-blind, cross-over, placebocontrolled RAND-CFR study with analyzable ECG recordings during both rest and exercise in three settings: baseline (before randomization), following placebo, and following 4 weeks of ranolazine (Shah et al., 2017) .
The study and medical records review were approved by the Partners Healthcare Institutional Review Board. The ECG recordings were scanned and converted into digital files. TWH was quantified by second central moment analysis without knowledge of treatment assignment.
| RAND-CFR trial design
A complete description of the methodology of the RAND-CFR study has been published (Shah et al., 2017) . Briefly, study patients had diabetes, baseline stable angina and/or exertional dyspnea, and exercise tolerance testing (ETT) of ≥3 metabolic equivalents. Patients with obstructive coronary artery disease (defined as ≥50% stenosis on invasive coronary angiography within the past year or on study protocol-mandated screening by coronary computer tomography angiography) and patients with a stress perfusion deficit >8.8% (suggestive of clinically significant ischemia and/or scar) on baseline myocardial perfusion positron emission tomography (PET) were excluded.
The order of ranolazine and placebo exposure was randomly assigned.
During the 4-week treatment periods, ranolazine (Gilead Sciences, Foster City, CA, USA) and matching placebo were administered as 500 mg by mouth twice daily for 1 week and increased to 1,000 mg by mouth twice daily for 3 weeks, as tolerated. Treatment compliance was measured by pill count. Patients and study investigators were blinded to treatments and treatment order throughout the study protocol.
MBF was measured at rest and in response to symptom-limited supine bicycle exercise using 13 N-ammonia as a PET flow tracer.
Heart rate, blood pressure, and 12-lead electrocardiogram (ECG)
were recorded at baseline and every minute during and after
ETT. An identical ETT protocol and workload were used for PET scans after each treatment arm. Absolute left ventricular MBF (ml/g/min) was computed from the dynamic rest and ETT imaging series using commercially available software and previously validated methods (Murthy et al., 2011) . Per-patient global coronary flow reserve (CFR) was calculated as the ratio of absolute MBF at ETT over rest for the entire left ventricle. Quantitation of MBF was performed by two operators blinded to the patient, treatment, and treatment order. To account for differences in resting cardiac workload, which can affect global rest left ventricular MBF, "corrected" CFR was calculated: corrected CFR = peak global LV left ventricular MBF/[(rest MBF/rest rate -pressure product) × 10,000].
| Electrocardiogram recordings
Recordings of standard 12-lead analog ECGs (25 mm/s, 10 mV/mm)
were printed for 12 s at rest and during ETT. The printed 12-lead ECG | 3 of 6 EVARISTO ET Al.
recordings were scanned with a high-resolution scanner. Patients without a complete set of V 4 , V 5 , or V 6 ECG leads, which are essential for TWH calculation, or whose tracings had significant noise artifact or baseline wander were excluded. The image-processing software, "ECGScan"
(AMPS-LLC, New York, NY), was used to extrapolate the ECG waveforms using an active modeling technique (Badilini, Erdem, Zareba, & Moss, 2005) . The resulting digital waveforms were converted into .txt files that could be imported into spreadsheets for subsequent analyses of TWH.
| Measurement of T-wave heterogeneity
The .txt files were imported to spreadsheets and leads V 4 , V 5 , and V 6 were plotted and superimposed. Second central moment analysis (Nearing & Verrier, 2003 , Verrier & Huikuri, 2017 was performed on the JT interval to measure TWH for every beat. The maximum splay in microvolts about the mean ECG waveform from the J point to end of the T wave for each patient during rest and ETT before and after ranolazine was reported.
Since TWH is measured over the entire JT waveform, it does not depend on the specific T-wave endpoint as do time-dependent indices of dispersion of repolarization such as Tpeak-Tend or QT c intervals.
| Statistics
Data are reported as means ± standard error of the mean (SEM).
Statistical differences were calculated using standard t-tests. Results within each group were compared using paired t-tests. Bonferroni correction was performed for multiple comparisons within or between groups, and 2-tailed p < .05 was considered significant.
| RESULTS
| Clinical characteristics
The age of the subjects in this study was 64 ± 1.6 years. All major clinical characteristics are presented in Table 1 , and exercise hemodynamics are summarized in Table 2 .
| Coronary flow reserve
The maximum corrected CFR value in the 16 patients in the current TWH substudy was 2.57 and the minimum was 1.13. The 75th percentile was 1.80. Thirteen (81.25%) of the 16 patients had CFR values <2, the threshold for hemodynamic significance (Kern et al., 2006) . At rest, corrected MBF was 0.96 ± 0.4 before drug, 0.92 ± 0.04 after placebo, and 0.93 ± 0.04 after ranolazine (p = .81, ANOVA). There was no correlation between MBF and TWH at rest before (r 2 = .07, p = .36) or after ranolazine (r 2 = .23, p = .06).
| T-wave heterogeneity
At baseline before randomization, TWH during rest was 54 ± 7 μV and was not altered following placebo (47 ± 6 μV, p = .47). After treatment with ranolazine, TWH during rest was significantly reduced by 28% (to 39 ± 5 μV, p = .002), as depicted in a representative patient (Figure 1) and shown in the groups (Figure 2 , left panel).
Unlike in the resting condition, ranolazine did not alter elevated TWH induced by exercise. Specifically, exercise increased TWH before drug by 37% (to 74 ± 11 μV, p = .07) and after placebo by 49%
(to 70 ± 8 μV, p = .03). Ranolazine did not reduce TWH during exercise (to 75 ± 16 μV) (Figure 2 , right panel) and there were no differences among the groups in that setting (p = .95, ANOVA).
| DISCUSSION
The present study uses a new noninvasive ECG-based method to quantify the effects of ranolazine on repolarization heterogeneity in symptomatic diabetic patients with non-flow-limiting coronary artery stenosis with diffuse atherosclerosis and/or microvascular T A B L E 1 Patient characteristics at baseline (n = 16) Age (years) 64 ± 1.6
Sex (M/F) 9/7 BMI 32 ± 1.8
Cardiovascular risk factors
Diabetes, n (%) 16 (100) Hypertension, n (%) 13 (81) Smoking, n (%) 9 (56) Hyperlipidemia, n (%) 16 (100)
Drug therapy
Beta-blockers, n (%) 7 (44) Calcium antagonists, n (%) 3 (19) ACE-inhibitors and/or ARBs, n (%) 12 (75) Statins, n (%) 15 (94) Antiaggregants, n (%) 4 (25) Nitrates, n (%) 4 (25) BMI, body mass index; ACE, angiotensin-converting enzyme; ARB, angiotensin-II receptor blocker. SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; RPP, rate pressure product.
T A B L E 2
dysfunction. We found ranolazine significantly reduced TWH in patients at rest, indicating a decrease in repolarization heterogeneity, a property linked to cardiovascular mortality and sudden cardiac death in a >5,600-subject Health Survey (Kenttä et al., 2016) . However, the drug was not capable of counteracting the increase in TWH associated with exercise.
| Prior studies
Ranolazine was developed as an antianginal agent but proved to have important antiarrhythmic properties (Antzelevitch et al., 2011) . Both cardioprotective effects appear to be related primarily to the drug's inhibition of I NaL rather than through its other actions of inhibiting peak I Na and I Kr . I NaL inhibition achieves its antiarrhythmic effects through reverse sodium-calcium exchange, ultimately preventing development of arrhythmogenic levels of cytosolic calcium. In preclinical studies, ranolazine was shown to reduce coronary artery stenosis-induced repolarization heterogeneity as assessed by T-wave alternans and by the threshold for vulnerability to ventricular fibrillation (Nieminen et al., 2011) . I NaL inhibition was implicated in the antiarrhythmic effect as the I Kr inhibitor E4031 decreased the ventricular fibrillation threshold in the same model. Recently, Justo et al. (2016) demonstrated that the highly selective I NaL inhibitor eleclazine significantly decreased stenosis-induced TWH in intact porcines. Thus, the protective effect of ranolazine appears to be due to direct actions on myocardial electrical properties, as coronary artery blood flow was maintained constant.
| Current investigation
In the baseline resting state, TWH was 54 ± 7 μV, an elevated level compared to 19 ± 2 μV obtained in a previous study of patients without apparent organic disease of the ventricular myocardium (Tan, Nearing, Josephson, & Verrier, 2013) . Placebo did not exert a significant change in TWH level (p = .47), but ranolazine significantly reduced TWH at rest to 39 ± 5 μV (p = .002). Although the reduction in TWH by ranolazine was moderate at 28%, this effect may reflect an important antiarrhythmic benefit, given that in the MERLIN trial the same dose of ranolazine substantially reduced ventricular tachyarrhythmias .
As cardiac metabolic demands are low at rest, and ST segments were not abnormal, it does not appear that ranolazine's reduction in TWH during rest was due to an anti-ischemic action. The possibility that the drug can alter cardiac electrophysiologic properties independent of an influence on coronary artery blood flow is consistent with preclinical evidence from Nieminen et al. (2011) and Justo et al. (2016) , who demonstrated protective antiarrhythmic effects of I NaL inhibition with ranolazine and eleclazine, respectively, during flowregulated coronary artery stenosis.
An additional mechanism for ranolazine's capacity to suppress TWH resides in the fact that I NaL inhibitors appear to be capable of reducing the arrhythmogenic effect of catecholamine-induced increases in I NaL . Specifically, two selective I NaL inhibitors, GS-967 (Bento et al., 2015) and eleclazine (Bacic et al., 2017) , have been shown to suppress catecholamine-induced VT and TWH.
Potentially relevant in this regard is evidence indicating significant autonomic dysfunction in patients with diabetes, with predominance in sympathetic tone (Carnethon et al., 2003) . Diabetes is associated with a decrease in high-frequency (HF) heart rate variability (HRV) and increase in low/high (LF/HF)-frequency HRV ratio. Further relevant to the present study are the findings that QT dispersion, an indicator of heterogeneity of repolarization, is elevated during rest in patients with diabetes (Arildsen et al., 1999; Cardoso et al., 2001; Wei et al., 1995) .
Thus, a component of ranolazine's effects on TWH may have been related to its reduction in enhanced I NaL due to hyperadrenergic activity associated with diabetes.
The inability of the drug to protect against the exercise-induced rise in TWH is puzzling, given its robust effect at rest. While the exact explanation is unclear, a possibility is that the heightened metabolic demands and/or excessive surges in exercise-related sympathetic activity overwhelmed the drug's effects in these patients with nonflow-limiting stenosis with diffuse atherosclerosis and/or microvascular dysfunction due to diabetes. The finding that ranolazine did not improve MBF and cardiac function during exercise, as reported in the parent study (Shah et al., 2017) , supports this surmise. Thus, it remains to be determined whether a longer period of ranolazine therapy might have been effective, given its success in improving CFR after 8 weeks Rest Exercise
TWH (μV)
Placebo Ranolazine p = 0.002 NS F I G U R E 1 Digitized tracings from a representative patient illustrating the reduction in T-wave heterogeneity (TWH) by ranolazine at rest compared with placebo. The complexes obtained from ECG leads V 4 , V 5 , and V 6 are QRS aligned. Note that with placebo, TWH is markedly elevated at 65 μV while it is reduced to 34 μV following ranolazine administration (Tagliamonte et al., 2015) and in reducing angina after 8 weeks in the Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina trial (TERISA, NCT01425359) (Kosiborod et al., 2013) .
| CONCLUSION
Ranolazine reduces TWH, an index of proarrhythmic repolarization abnormalities, in symptomatic patients with diabetes and non-flowlimiting stenosis <50% with diffuse atherosclerosis and/or microvascular dysfunction. The precise mechanisms involved remain to be determined but do not appear to be linked to changes in MBF.
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